BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250812T104500Z
LAST-MODIFIED:20250812T104500Z
UID:41714-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:8th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs\, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative\, cancer and rare disorders. In 2025 alone\, the field has seen major collaborations\, including Wayfinder Biosciences with Daiichi Sankyo\, Ono Pharmaceutical with Reborna Biosciences\, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence. \nNow in its 8th year\, the RNA-Targeted Drug Discovery & Development Summit returns as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators\, covalent drugs\, proximity inducers and direct RNA binders.\nJoin 25+ world-class speakers from leaders like PTC Therapeutics\, ReviR Therapeutics\, Remix Therapeutics\, Rgenta Therapeutics\, Arrakis Therapeutics and more this December to gain the connections\, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond. \nStep into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data\, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA. \nThis year\, join 80+ experts in RNA biology\, drug discovery\, medicinal chemistry\, and structural biology to gain the latest data on visualizing dynamic RNA structures\, identifying functional binders\, improving selectivity\, enhancing delivery stability and achieving oral bioavailability. \nWhether you’re focused on RNA splice modulators\, covalent binders\, proximity inducing drugs\, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic. \nConnect with your global community at the world’s only meeting for RNA-targeted drug experts. \nTo know more visit: https://ter.li/rcvdor
URL:http://www.pharmajournalist.com/event/8th-rna-targeted-drug-discovery-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250820T122909Z
LAST-MODIFIED:20250820T122909Z
UID:41738-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Innovation in Obesity Therapeutics Summit
DESCRIPTION:The 2nd Innovation in Obesity Therapeutics Summit will return to San Diego this December. Hear from the titans of the pharmaceutical industry\, including Novo Nordisk\, Eli Lilly and Boehringer Ingelheim\, who will share their groundbreaking research and strategies. The pressure is on to develop best-in-class treatments that transform patient lives. \nDon’t miss this pivotal opportunity to network with 60+ experts in the field of obesity\, forge crucial collaborations\, and be part of the solution. \nFind out more here: https://ter.li/vnapww
URL:http://www.pharmajournalist.com/event/2nd-innovation-in-obesity-therapeutics-summit/
LOCATION:DoubleTree by Hilton Hotel San Diego – Mission Valley\, 7450 Hazard Center Dr\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250829T120338Z
LAST-MODIFIED:20250829T120338Z
UID:41820-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Regulatory Affairs Summit
DESCRIPTION:With major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nFind out more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-regulatory-affairs-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250905T114029Z
LAST-MODIFIED:20250905T114054Z
UID:41892-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:5th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Navigate New FDA Leadership\, Harness AI-Powered Submissions & Align Technical Innovation with the Latest Nonclinical\, Clinical & CMC Guidance to Overcome Regulatory Challenges and Accelerate Your Path to Clinic & Market \nWith major FDA changes already reshaping the regulatory landscape – and global agencies ramping up scrutiny – 2025 is a pivotal year for cell and gene therapy regulatory professionals. With CBER leadership changes\, new FDA draft guidance on post-approval CMC\, and potency assays facing heightened scrutiny\, the environment is rapidly evolving. Global efforts to align expectations are also gaining momentum\, with ANVISA and Health Canada joining harmonization initiatives\, and ICH Q12 implementation for CGTs underway. \nThe 2nd Cell & Gene Therapy Regulatory Affairs Summit is the only industry-led event focused exclusively on CGT regulatory strategy. Join 80+ experts this December in Washington\, D.C. for real-world case studies\, insights from regulators\, and deep dives into IND-to-BLA planning\, global alignment\, and emerging modalities. \nIf you’re navigating nonclinical\, clinical\, or CMC submissions\, this is your essential forum to stay ahead of shifting expectations and accelerate CGT approvals in 2025 and beyond. \nLearn more: https://ter.li/c211fx
URL:http://www.pharmajournalist.com/event/5th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Washington Marriott Capitol Hill\, 175 L St NE\, Washington\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250919T105408Z
LAST-MODIFIED:20250919T105408Z
UID:41976-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:6th Gene Therapy for Ophthalmic Disorders Summit
DESCRIPTION:The 6th Gene Therapy for Ophthalmic Disorders Summit returns to Raleigh\, North Carolina\, as the leading industry forum dedicated to accelerating the development of gene therapies for both rare and common eye diseases. With irreversible vision loss progressing rapidly in many conditions\, gene therapy continues to emerge as a critical one-time intervention that can preserve and restore sight for patients in need. \nMomentum in 2025 is stronger than ever. Kriya Therapeutics is advancing its preclinical pipeline\, Opus Genetics and SpliceBio are progressing into early trials\, while Ocugen\, 4D Molecular Therapeutics\, and AbbVie are racing toward BLA approval. Against this backdrop of progress\, challenges around endpoint selection\, funding strategies\, and safe delivery methods remain at the forefront. The summit provides a unique platform to tackle these issues head-on and drive forward meaningful breakthroughs. \nAttendees will gain access to exclusive data and insights\, including preclinical updates from Opus Genetics\, Coave Therapeutics\, and Axovia Therapeutics\, alongside pivotal 2025 clinical progress shared by Ocugen\, Adverum Biotechnologies\, and Beacon Therapeutics. A major highlight is the Interview the Investor session with James Kasuboski\, Partner & Head of Research at Luma Group\, where attendees will hear directly from investors on the criteria shaping ophthalmic gene therapy funding and strategies for building sustainable development approaches. \nAdditional sessions will spotlight patient-led regulatory engagement\, comparative analyses of delivery approaches\, and strategies for optimizing trial design and patient retention. With a carefully balanced agenda – equally split between preclinical and clinical content – this meeting provides a comprehensive view of the ophthalmic gene therapy pipeline. \nFeaturing 18+ senior expert speakers\, 3+ hours of clinical data\, 2+ hours of preclinical research\, and 6+ hours of networking opportunities\, the summit unites biopharma leaders\, investors\, and innovators to accelerate progress from IND through to late-stage clinical development. \nJoin us in Raleigh to connect with decision-makers across the ophthalmic gene therapy value chain\, uncover the next wave of breakthroughs beyond Luxturna\, and ensure your therapy reaches patients faster. \n View the full event program on our website here: https://ter.li/0duhtz
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-for-ophthalmic-disorders-summit/
LOCATION:DoubleTree by Hilton Raleigh Midtown\, 2805 Highwoods Blvd\, Raleigh\, NC\, 27604\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251202
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250805T115734Z
LAST-MODIFIED:20250805T120701Z
UID:41643-1764633600-1764892799@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:Ever since the field-defining studies in Nature Medicine and the New England Journal demonstrated that cell therapies could hold lasting potential in lupus and beyond\, the field has grown from strength to strength. With a surge of billion-dollar investments\, the release of new groundbreaking data\, and recent real-world clinical progression\, the autoimmune cell therapy field is poised for clinical and commercial success. \nThe 3rd Cell Therapy for Autoimmune Disease Summit (December 2-4 | Philadelphia\, PA) returns at a pivotal time\, providing first-hand insights and case studies needed to keep your team ahead in this fast-evolving space. Reconnect with 130+ scientific pioneers\, with expertise spanning CAR-T\, Treg\, in vivo and NK cell therapies\, as they unveil the latest clinical data and cutting-edge innovations redefining the chronic care of autoimmune indications. \nAccess Your Brand-New 2025 Agenda Copy! \nLearn directly from industry titans including Cabaletta Bio\, Kyverna Therapeutics\, Umoja Biopharma\, Cartesian Therapeutics\, Century Therapeutics\, Artiva Biotherapeutics and Novartis\, to benchmark your current strategies and gain a competitive edge amongst your peers to accelerate your lead candidate from preclinical innovation to clinical success. \nWhether you are preparing for your first clinical trials\, or making the transition into later phases\, our carefully curated two-tracked agenda (now expanded to the Workshop Day!) has content tailored for you. \n\nPreclinical & Translational: Address challenges in antigen selection\, delve into autologous and allogeneic translational strategies\, and discuss alternatives to B-cell depletion\, to bring the next wave of therapies to the clinic.\nClinical: Unpack trial design\, evaluate long-term clinical outcomes\, share regulatory strategies\, and learn how to operationalize studies for broader patient access.\n\nWith cell therapy companies increasingly targeting autoimmune diseases\, and autoimmune companies continuing to embrace cellular approaches\, ensure you join the industry’s definitive meeting committed to transforming the promise of cell therapies in autoimmunity into reality. \nEvent Guide | Register | Learn More
URL:http://www.pharmajournalist.com/event/3rd-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Sheraton Philadelphia Downtown\, 201 N 17th Street\, Philadelphia\, PA\, 19103\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251203
DTEND;VALUE=DATE:20251205
DTSTAMP:20260515T025707
CREATED:20250827T112407Z
LAST-MODIFIED:20250827T112407Z
UID:41782-1764720000-1764892799@www.pharmajournalist.com
SUMMARY:14th Tumour Models Summit London
DESCRIPTION:With the European oncology market increasingly focused on emerging modalities\, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody\, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions\, there has never been a more important year to stay up to date with the latest innovations in tumour modelling. \nAs the longest-standing forum from the world-renowned Tumour Models event series\, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma\, biotech\, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic. \nDownload the event guide for full details: https://ter.li/hsztzb
URL:http://www.pharmajournalist.com/event/14th-tumour-models-summit-london/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR